FDA unveils revamped consumer site

Share this article:
The FDA has officially launched its new consumer-facing Web site and introduced a monthly e-newsletter as part of a new initiative to improve online communications.

The site overhaul “reflects an agency-wide recognition that we can and must do a better job at Web communications,” based on “our own experiences as well as user feedback,” FDA spokeswoman Crystal Rice said.

The new consumer Web page at www.fda.gov/consumer, will present public health information and developments, links to useful information and interactive content, agency officials said. 

As part of the FDA’s new online push, the agency has done away with its FDA Consumer print publication and replaced it with a free monthly newsletter titled “FDA Consumer Health Information.”

The e-newsletter, which can also be found at www.fda.gov/consumer/consumernews.html, will alert consumers to content contained on the Web page.

“The Web page and newsletter are important new consumer resources that will feature timely stories on pressing FDA topics, provide links to our most requested information and include interactive content,” said FDA commissioner Andrew von Eschenbach in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...